Data for: 3364379

Published: 2 April 2019| Version 1 | DOI: 10.17632/9drsxxdxcs.1
Contributor:
V N L CHAITANYA Motamarri

Description

The major cause for the poor rate of successful multi-targeting anticancer drugs on the market is incomplete research, limited to only in-vitro or in-silico or phytochemical characterisation, with no further attempts at optimizing these drug leads to move them along the development pipeline. It is important to explore a drug lead to its fullest potential as a drug candidate and eventually as a successful drug. It is in this light that the current study is undertaken to evaluate the efficacy of ruscogenin, a saponin isolated from the weed Cytisus scoparius (Fabaceae), as a dual top drugging agent based on the published in-silico data (Chaitanya et al., 2015).

Files

Categories

Anticancer Drug

Licence